Applied DNA Sciences held its 2024 annual meeting on September 30, where shareholders approved all four key proposals. The meeting resulted in the successful election of six directors to serve until the 2025 annual meeting, and the ratification of Marcum LLP as the company's independent registered public accounting firm.Significantly, shareholders granted the board discretionary authority for 12 months to implement a reverse stock split at a ratio ranging from 1:5 to 1:50, with the specific ratio to be determined by the board. Additionally, stockholders approved the exercisability of common stock purchase warrants issued in May 2024, along with the issuance of underlying common stock, in accordance with Nasdaq Listing Rule 5635(d).

Applied DNA Sciences held its 2024 annual meeting on September 30, where shareholders approved all four key proposals. The meeting resulted in the successful election of six directors to serve until the 2025 annual meeting, and the ratification of Marcum LLP as the company's independent registered public accounting firm.Significantly, shareholders granted the board discretionary authority for 12 months to implement a reverse stock split at a ratio ranging from 1:5 to 1:50, with the specific ratio to be determined by the board. Additionally, stockholders approved the exercisability of common stock purchase warrants issued in May 2024, along with the issuance of underlying common stock, in accordance with Nasdaq Listing Rule 5635(d).